[go: up one dir, main page]

 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (890)

Search Parameters:
Keywords = endoscopic surgery

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
12 pages, 22352 KiB  
Case Report
Multiple Small Bowel Cavernous Hemangiomatosis: Case Report and Literature Review
by Francesca Ré, Salvatore Carrabetta, Eugenio Merlo and Pietro Bisagni
Medicina 2024, 60(10), 1664; https://doi.org/10.3390/medicina60101664 - 10 Oct 2024
Viewed by 390
Abstract
A 79 year old female individual presented to the hospital and complained of 1 month melena and anemia due to chronic gastrointestinal bleeding because of cavernous hemangiomatosis of the small bowel. After undergoing an initial video laparoscopic jejunal–ileal resection surgery 7 days after [...] Read more.
A 79 year old female individual presented to the hospital and complained of 1 month melena and anemia due to chronic gastrointestinal bleeding because of cavernous hemangiomatosis of the small bowel. After undergoing an initial video laparoscopic jejunal–ileal resection surgery 7 days after first hospitalization, given the persistence of anemia, she underwent laparotomic duodenojejunal resection surgery again 2 months later. Multiple cavernous hemangiomatosis is a rare vascular disease (7–10% of all benign small bowel tumors), and it often manifests with bleeding, which may be occult or massive; more rarely, it manifests with intestinal occlusion or perforation. Diagnoses often require the use of multiple radiological and endoscopic methods; video capsule endoscopy has significantly increased the diagnostic rate. The gold standard of treatment is surgical resection, whenever possible, balancing the need for radicality with the possible metabolic consequences of massive small intestine resections. Full article
(This article belongs to the Section Surgery)
Show Figures

Figure 1

Figure 1
<p>Angio CT contrast blushing in the proximal small bowel (first image).</p>
Full article ">Figure 2
<p>Angio CT contrast blushing in the proximal small bowel (late image).</p>
Full article ">Figure 3
<p>Laparoscopic first surgery intraoperative image showing multiple lesions in the proximal small bowel.</p>
Full article ">Figure 4
<p>Angio CT showing multiple hyperdense endoluminal images at the fourh duodenum and first jejunal loop up to surgical anastomosis referable to contrast spillage.</p>
Full article ">Figure 4 Cont.
<p>Angio CT showing multiple hyperdense endoluminal images at the fourh duodenum and first jejunal loop up to surgical anastomosis referable to contrast spillage.</p>
Full article ">Figure 5
<p>Intraoperative image of the second surgery showing multiple localization in the transverse colon and first jejunal loop.</p>
Full article ">Figure 6
<p>Proximal section of the duodenojejunal junction during the second surgery.</p>
Full article ">Figure 7
<p>Hematoxylin eosin histology of the small bowel showing vascular submucosal sinus-like spaces containing blood separated by connective tissue; normal mucosal layer with crypts and villi is present too.</p>
Full article ">Figure 8
<p>Hematoxylin eosin histology showing in detail endothelial lakes filled with blood and sinus-like spaces containing blood separated by connective matrix.</p>
Full article ">
20 pages, 861 KiB  
Systematic Review
A Comprehensive Systematic Review on Functional Results, Speech and Swallowing Outcomes after Trans-Oral Robotic Surgery for Oropharyngeal Squamous Cell Cancer
by Pierre Guarino, Francesco Chiari, Sara Cordeschi, Pasquale D’Alessio, Carla Ingelido, Giovanni Motta, Livio Presutti, Gabriele Molteni and Claudio Donadio Caporale
J. Clin. Med. 2024, 13(20), 6039; https://doi.org/10.3390/jcm13206039 - 10 Oct 2024
Viewed by 383
Abstract
Background: Transoral robotic surgery (TORS) is nowadays considered a valuable minimally invasive approach to treat oropharyngeal squamous cell carcinoma (OPSCC). The aim of this technique is to improve functional preservation and reduce morbidity with excellent oncologic outcomes compared to the traditional transoral approach [...] Read more.
Background: Transoral robotic surgery (TORS) is nowadays considered a valuable minimally invasive approach to treat oropharyngeal squamous cell carcinoma (OPSCC). The aim of this technique is to improve functional preservation and reduce morbidity with excellent oncologic outcomes compared to the traditional transoral approach and chemoradiotherapy (CRT). The purpose of this systematic review is to assess an exhaustive overview of functional outcomes of TORS for OPSCC by evaluating several parameters reported in the available literature, such as the prevalence and dependence of tracheotomy, feeding tubes (FTs) and percutaneous endoscopic gastrostomy (PEG), the length of hospitalization, swallowing scores, speech tests and quality of life (QoL) questionnaires. Methods: A systematic literature review has been performed following the PRISMA 2020 checklist statement. A computer-aided search was carried out using an extensive set of queries on the Embase/PubMed, Scopus and Web of Sciences databases relating to papers published from 2007 to 2024. Results: A total of 28 papers were systematically reviewed, reporting 1541 patients’ data. The mean time of hospitalization was 6 days. A planned tracheotomy was performed in 8% of patients with a mean time of removal of 8 days. The prevalence and dependence of FT was 60% and 10%, respectively. Moreover, the presence of a high-stage T tumor with the contextual requirement of adjuvant therapies, the involvement of base tongues and the patient’s age being >55 years increased the risk of requiring an FT and PEG. Swallowing and long-term QoL outcomes highlight the superiority of the TORS approach alone compared to TORS with adjuvant therapies. Conclusions: TORS presented various favorable functional outcomes compared to other surgical approaches and primary CRT. However, adjuvant therapies after TORS strongly reduced the advantage of the robotic procedure, thus suggesting that T1 and T2 tumors may benefit mainly from TORS alone. Full article
(This article belongs to the Special Issue New Advances in Nasopharyngeal and Oropharyngeal Cancer Treatment)
Show Figures

Figure 1

Figure 1
<p>Flow chart of the study.</p>
Full article ">
113 pages, 45090 KiB  
Conference Report
Abstracts of the Italian Society of Thoracic Endoscopy (SIET) 2024 Annual Congress
by Carmelina Cristina Zirafa, Mohsen Ibrahim, Lorenzo Corbetta, Lorenzo Rosso, Piero Candoli, Beatrice Manfredini, Giovanni Galluccio, Cecilia Menna, Rocco Trisolini, Sara Ricciardi, Gaetano Romano, Giuseppe Cardillo, Franca Melfi and Federico Raveglia
J. Clin. Med. 2024, 13(19), 5954; https://doi.org/10.3390/jcm13195954 (registering DOI) - 7 Oct 2024
Viewed by 639
Abstract
We are pleased to introduce the abstracts of the XXIII National Congress of the Italian Society of Thoracic Endoscopy (SIET), which will be held in Florence from 17 to 19 October 2024. The principal objectives of SIET are to (1) Promote research and [...] Read more.
We are pleased to introduce the abstracts of the XXIII National Congress of the Italian Society of Thoracic Endoscopy (SIET), which will be held in Florence from 17 to 19 October 2024. The principal objectives of SIET are to (1) Promote research and innovation in the fields of thoracic surgery and endoscopy, facilitating the development and implementation of innovative techniques and technologies; (2) Provide education and training for surgeons, endoscopists, pulmonologists and other related specialties; and (3) Facilitate the exchange of knowledge with the aim of creating a cohesive and active scientific community. The Congress will address the integration of traditional surgical and endoscopic techniques with emerging technologies, with the goal of promoting innovation and education among professionals. The theme of integration will be explored throughout the programme, with a particular focus on the collaborative efforts of different medical specialties to improve patient outcomes. This event will host a multidisciplinary cohort comprising thoracic surgeons, endoscopists, pulmonologists, oncologists, pathologists, radiologists and anaesthetists, who will assume a pivotal role in the multidisciplinary sessions of the scientific programme. The Congress will include several core areas of expertise, including lung cancer, interventional endoscopy, pathology, and upper airway reconstruction. Emphasis will be placed on both the theoretical aspects of these subjects and their practical applications in patient care. The theme of integration will be explored throughout the programme, with particular attention on the impact of recent technological developments in the fields of thoracic surgery and endoscopy. Additionally, the Congress will examine the contributions of allied health professionals, including nurses, physiotherapists, and speech pathologists, to patient care. Full article
(This article belongs to the Section General Surgery)
Show Figures

Figure 1

Figure 1
<p>Positron emission tomography (PET)/computed tomography (CT) scan of a right interlobar lymph node (<b>A</b>) and transvascular EBUS−TBNA of the lymph adenopathy (<b>B</b>). CT (<b>C</b>) and PET/CT (<b>D</b>) scan of a right upper lobe pulmonary nodule and transvascular EUS−B-FNA of the lung lesions (<b>E</b>).</p>
Full article ">Figure 2
<p>Survival analysis in NSCLC patients who underwent open surgery, VATS and RATS.</p>
Full article ">Figure 3
<p>NTM cavities pre and post valve placement.</p>
Full article ">Figure 4
<p>Diagnostic and therapeutic process.</p>
Full article ">Figure 5
<p>Stent in anastomotic dehiscence.</p>
Full article ">Figure 6
<p>Univariate analysis for DFS.</p>
Full article ">Figure 7
<p>Evaluation of severity of emphysema and HF integrity.</p>
Full article ">Figure 8
<p>(<b>A</b>,<b>B</b>) Scan magnification of lung cryobiopsies: H&amp;E (<b>A</b>) and ex-vivo confocal microscopy (<b>B</b>). (<b>C</b>,<b>D</b>) Higher magnification.</p>
Full article ">Figure 9
<p>Example of tracheobronchial foreign body (TFB) retrieved from the airways of adult patients (clockwise, from left to right): dental device for root canal treatment, nail, coin, grape.</p>
Full article ">Figure 10
<p>Crown-cut TBNB needle.</p>
Full article ">Figure 11
<p>Diagnostic Yield (DY) of 22 G and 25 G TBNB needles, divided per year and EUS-B-FNB DY.</p>
Full article ">Figure 12
<p>Dual-Port Fully Robotic approach port mapping: 3–4 cm working port using a wound protector (Alexis wound retractor XS<sup>®</sup>, Applied Medical, Rancho Santa Margarita, CA, USA) in the fifth intercostal space, along the posterior axillary line and 1.2 cm working port on the eight intercostal space, along the midaxillary line.</p>
Full article ">Figure 13
<p>Survival analysis.</p>
Full article ">Figure 14
<p>Prognostic factor analysis.</p>
Full article ">Figure 15
<p>Right paratracheal enlargement (indicated by the red arrow) at chest CT (<b>A</b>), and at FDG PET/CT, with SUVmax 6.0 (<b>B</b>); EBUS-TBNA on right paratracheal enlargement (<b>C</b>); ROSE with diff quick stain, 100× magnification: fibrillar material, lymphocytes and macrophages (<b>D</b>).</p>
Full article ">Figure 16
<p>Patients managed by LCP during the years.</p>
Full article ">Figure 17
<p>Preoperative CT, showing pulmonary lesion in red circle (<b>A</b>) and PET (<b>B</b>). Surgical port mapping (<b>C</b>).</p>
Full article ">Figure 18
<p>Postoperative chest X-ray.</p>
Full article ">Figure 19
<p>Post operative chest Ct scan, showing kinking of the lower lobar bronchus (yellow circle).</p>
Full article ">Figure 20
<p>Chest X-ray after surgical revision.</p>
Full article ">Figure 21
<p>Silver-colored endobronchial lesion, highlighting the characteristic silver hue of the lesion during the endoscopic examination.</p>
Full article ">Figure 22
<p>Chest X-ray showing left spontaneous pneumothorax (<b>A</b>); Chest X-ray showed an air-fluid level in left apical paramediastinal region after chest tube positioning (<b>B</b>); Chest Ct-scan (<b>C</b>); Surgical specimen (<b>D</b>).</p>
Full article ">Figure 23
<p>Pre LVRS TC-scan.</p>
Full article ">Figure 24
<p>Lung scintigrafy.</p>
Full article ">Figure 25
<p>After LVRS TC-scan (nodule).</p>
Full article ">Figure 26
<p>1 month X-ray chest.</p>
Full article ">Figure 27
<p>Chest angio-CT scan shows azygos ectasia (arrow).</p>
Full article ">Figure 28
<p>Intraoperative view of azygos vein.</p>
Full article ">Figure 29
<p>Intraoperative view after azygos section.</p>
Full article ">Figure 30
<p>Lymphadenopathy of station 4R.</p>
Full article ">Figure 31
<p>PE contiguous to the primary pulmonary lesion.</p>
Full article ">Figure 32
<p>EBUS view of round, centimeter-sized lesion in continuity with the vascular wall and surrounded by blood flow.</p>
Full article ">Figure 33
<p>Chest CT scan at admission.</p>
Full article ">Figure 34
<p>Preoperative PET.</p>
Full article ">Figure 35
<p>Radiological and pathological features of the presented case. (<b>a</b>) Diffuse parietal pleura thickening and bilateral organized pleural effusion on contrast CT of the chest. (<b>b</b>,<b>c</b>) Contrast chest MR showing bilateral pleural effusion with multiple saccular aspects due to partially bloody content. In the contrast phase, bilateral linear contrast enhancements of the pleura and laminar areas of restricted protonic diffusivity were evident. (<b>d</b>) Microscopic pathological findings: irregularly shaped anastomosing vascular channels lined by atypical endothelial cells with a highly infiltrative architecture and poor demarcation (hematoxylin and eosin, magnification 10×).</p>
Full article ">Figure 36
<p>Broncoscopy.</p>
Full article ">Figure 37
<p>Irregularly shaped trachea with multiple cartilaginous nodules.</p>
Full article ">Figure 38
<p>Ultiple cartilaginous nodules present in the carina and main bronchi.</p>
Full article ">
13 pages, 3096 KiB  
Article
Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer
by Tereza Hálková, Bohuš Bunganič, Eva Traboulsi, Marek Minárik, Miroslav Zavoral and Lucie Benešová
Genes 2024, 15(10), 1302; https://doi.org/10.3390/genes15101302 - 7 Oct 2024
Viewed by 767
Abstract
Background/Objectives: Although the overall survival prognosis of patients in advanced stages of pancreatic ductal adenocarcinoma (PDAC) is poor, typically ranging from days to months from diagnosis, there are rare cases of patients remaining in therapy for longer periods of time. Early estimations of [...] Read more.
Background/Objectives: Although the overall survival prognosis of patients in advanced stages of pancreatic ductal adenocarcinoma (PDAC) is poor, typically ranging from days to months from diagnosis, there are rare cases of patients remaining in therapy for longer periods of time. Early estimations of survival prognosis would allow rational decisions on complex therapy interventions, including radical surgery and robust systemic therapy regimens. Understandably, there is great interest in finding prognostic markers that can be used for patient stratification. We determined the role of various KRAS mutations in the prognosis of PDAC patients using biopsy samples and circulating tumor DNA. Methods: A total of 118 patients with PDAC, clinically confirmed by endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNB), were included in the study. DNA was extracted from cytological slides following a standard cytology evaluation to ensure adequacy (viability and quantity) and to mark the tumor cell fraction. Circulating tumor DNA (ctDNA) was extracted from plasma samples of 45 patients in stage IV of the disease. KRAS mutations in exons 12 and 13 were detected by denaturing capillary electrophoresis (DCE), revealing a minute presence of mutation-specific heteroduplexes. Kaplan–Meier survival curves were calculated for individual KRAS mutation types. Results:KRAS mutations were detected in 90% of tissue (106/118) and 44% of plasma (20/45) samples. All mutations were localized at exon 2, codon 12, with G12D (GGT > GAT) being the most frequent at 44% (47/106) and 65% (13/20), followed by other types including G12V (GGT > GTT) at 31% (33/106) and 10% (2/20), G12R (GGT > CGT) at 17% (18/106) and 10% (2/20), G12C (GGT/TGT) at 5% (5/106) and 0% (0/20) and G12S (GGT/AGT) at 1% (1/106) and 5% (1/20) in tissue and plasma samples, respectively. Two patients had two mutations simultaneously (G12V + G12S and G12D + G12S) in both types of samples (2%, 2/106 and 10%, 2/20 in tissue and plasma samples, respectively). The median survival of patients with the G12D mutation in tissues was less than half that of other patients (median survival 101 days, 95% CI: 80–600 vs. 228 days, 95% CI: 184–602), with a statistically significant overall difference in survival (p = 0.0080, log-rank test), and furthermore it was less than that of all combined patients with other mutation types (101 days, 95% CI: 80–600 vs. 210 days, 95% CI: 161–602, p = 0.0166). For plasma samples, the survival of patients with this mutation was six times shorter than that of patients without the G12D mutation (27 days, 95% CI: 8–334 vs. 161 days, 95% CI: 107–536, p = 0.0200). In contrast, patients with detected KRAS G12R in the tissue survived nearly twice as long as other patients in the aggregate (286 days, 95% CI: 70–602 vs. 162 days, 95% CI: 122–600, p = 0.0374) or patients with other KRAS mutations (286 days, 95% CI: 70–602 vs. 137 days, 95% CI: 107–600, p = 0.0257). Conclusions: Differentiation of specific KRAS mutations in EUS-FNB and ctDNA (above all, the crucial G12D and G12R) is feasible in routine management of PDAC patients and imperative for assessment of prognosis. Full article
(This article belongs to the Section Human Genomics and Genetic Diseases)
Show Figures

Figure 1

Figure 1
<p>If a mutation is present in the sample (in this case <span class="html-italic">KRAS</span> mutation), four peaks are visible in the electropherogram: wildtype homoduplex, mutant homoduplex and two heteroduplexes (from left to right). The figure illustrates electropherograms of standard samples with the most commonly detected <span class="html-italic">KRAS</span> mutations in PDAC tissues. Note that different <span class="html-italic">KRAS</span> mutations have different positions of peaks in the electroferogram. If no mutation is present in the sample, only one peak corresponding to the wildtype homoduplex is visible in the electropherogram.</p>
Full article ">Figure 2
<p>Overall survival curves (<b>a</b>) according to the presence of <span class="html-italic">KRAS</span> mutations in tumor tissue and (<b>b</b>) according to the presence of the three most common <span class="html-italic">KRAS</span> mutation subtypes in tumor tissue.</p>
Full article ">Figure 3
<p>Differences in OS of (<b>a</b>) patients with and without <span class="html-italic">KRAS</span> G12D in tumor tissue and (<b>b</b>) patients with <span class="html-italic">KRAS</span> G12D and patients with other <span class="html-italic">KRAS</span> mutations in tumor tissue.</p>
Full article ">Figure 4
<p>Differences in OS of (<b>a</b>) patients with and without <span class="html-italic">KRAS</span> G12V in tumor tissue and (<b>b</b>) patients with <span class="html-italic">KRAS</span> G12V and patients with other <span class="html-italic">KRAS</span> mutations in tumor tissue.</p>
Full article ">Figure 5
<p>Differences in OS of (<b>a</b>) patients with and without <span class="html-italic">KRAS</span> G12R in tumor tissue and (<b>b</b>) patients with <span class="html-italic">KRAS</span> G12R and patients with other <span class="html-italic">KRAS</span> mutations in tumor tissue.</p>
Full article ">Figure 6
<p>Overall survival curves according to the presence of <span class="html-italic">KRAS</span> mutations in ctDNA.</p>
Full article ">Figure 7
<p>Differences in OS of (<b>a</b>) patients with and without <span class="html-italic">KRAS</span> G12D in ctDNA and (<b>b</b>) patients with <span class="html-italic">KRAS</span> G12D and patients with other <span class="html-italic">KRAS</span> mutations in ctDNA.</p>
Full article ">
14 pages, 1975 KiB  
Article
Tolerability and Safety Assessment of Adjuvant Chemoradiotherapy with S-1 after Limited Surgery for T1 or T2 Lower Rectal Cancer
by Norikatsu Miyoshi, Mamoru Uemura, Shingo Noura, Masayoshi Yasui, Junichi Nishimura, Mitsuyoshi Tei, Chu Matsuda, Shunji Morita, Akira Inoue, Hiroki Tamagawa, Yukako Mokutani, Shinichi Yoshioka, Makoto Fujii, Shinya Kato, Yuki Sekido, Takayuki Ogino, Hirofumi Yamamoto, Kohei Murata, Yuichiro Doki and Hidetoshi Eguchi
Cancers 2024, 16(19), 3360; https://doi.org/10.3390/cancers16193360 - 30 Sep 2024
Viewed by 411
Abstract
Background: The short-term outcomes of chemoradiotherapy (CRT) with S-1 (a combination of tegafur, gimeracil, and oteracil) following limited surgery for patients with T1 or T2 lower rectal cancer have shown encouraging results. Objectives: This study was designed to delve deeper into the long-term [...] Read more.
Background: The short-term outcomes of chemoradiotherapy (CRT) with S-1 (a combination of tegafur, gimeracil, and oteracil) following limited surgery for patients with T1 or T2 lower rectal cancer have shown encouraging results. Objectives: This study was designed to delve deeper into the long-term outcomes of CRT with S-1 after limited surgery, with the goal of evaluating both the long-term efficacy and potential risks associated with this treatment approach in patients diagnosed with T1 or T2 lower rectal cancer. Methods: This was conducted as a multicenter, single-arm, prospective phase II trial. The patient population consisted of individuals clinically diagnosed with either T1 or T2 lower rectal or anal canal cancer, with a maximum tumor diameter of 30 mm and classified as N0 or M0. Patients underwent local excision or endoscopic resection. After surgery, CRT with S-1 was administered to patients meeting several criteria, including the confirmation of well-differentiated or moderately differentiated adenocarcinoma, negative surgical margins, submucosal invasion depth of ≥1000 µm, and high tumor-budding grade (2/3). The primary endpoint of this study was relapse-free survival, while secondary endpoints included local recurrence-free survival, overall survival, anal sphincter preservation rate, and safety. Results: A total of 52 patients were included, with pathological diagnoses revealing T1 in 36 patients and T2 in 16 patients. The 3-year and 5-year relapse-free survival rates were 90.17% and 85.87%, respectively. The 3-year and 5-year local recurrence-free survival rates were 90.17% and 88.07%, respectively, while the 3-year and 5-year overall survival rates were 94.03% and 91.94%, respectively. Conclusions: CRT with S-1 after limited surgery for T1 lower rectal cancer demonstrated favorable outcomes in terms of recurrence, survival, and local control rates while effectively maintaining anal function in patients. However, further treatment approaches may be necessary to improve outcomes for patients diagnosed with stage T2 lower rectal cancer Full article
(This article belongs to the Special Issue The Survival of Colon and Rectal Cancer)
Show Figures

Figure 1

Figure 1
<p>Relapse-free survival rates. Kaplan–Meier curve showing the relapse-free survival rates of patients with T1 or T2 lower rectal cancer treated with CRT using S-1 after limited surgery. The three-year and five-year relapse-free survival rates were 90.17% and 85.87%, respectively. The short black lines on the survival curve indicate censored data.</p>
Full article ">Figure 2
<p>Local recurrence-free survival rates. Kaplan–Meier curve showing the three-year and five-year local recurrence-free survival rates of patients with T1 or T2 lower rectal cancer treated with CRT using S-1 after limited surgery. The three-year and five-year local recurrence-free survival rates were 90.17% and 88.07%, respectively. The short black lines on the survival curve indicate censored data.</p>
Full article ">Figure 3
<p>Cumulative local recurrence rates. Kaplan–Meier curve representing the cumulative local recurrence rates in patients with T1 or T2 lower rectal cancer treated with CRT using S-1 after limited surgery over a period of five years. The three-year and five-year local relapse rates were 9.83% and 11.93%, respectively. The short black lines on the survival curve indicate censored data.</p>
Full article ">Figure 4
<p>Overall survival rates. Kaplan–Meier curve depicting the overall survival rates of patients with T1 or T2 lower rectal cancer treated with CRT using S-1 after limited surgery. The overall survival rates at three and five years were 94.03% and 91.94%, respectively. The short black lines on the survival curve indicate censored data.</p>
Full article ">Figure 5
<p>Anal sphincter preservation rate. Kaplan–Meier curve representing the anal-preserving survival rates in patients with T1 or T2 lower rectal cancer treated with CRT using S-1 after limited surgery over a period of five years. The three-year and five-year local recurrence rates were 92.06% and 87.83%, respectively. The short black lines on the survival curve indicate censored data.</p>
Full article ">Figure 6
<p>Survival and recurrence rates stratified by SM and MP invasion. (<b>a</b>) Kaplan–Meier curves for local recurrence-free survival stratified by SM and MP invasion. (<b>b</b>) Kaplan–Meier curves for relapse-free survival stratified by SM and MP invasion. (<b>c</b>) Kaplan–Meier curves for overall survival stratified by SM and MP invasion. The MP group exhibited significantly worse local recurrence-free survival and relapse-free survival than the SM group. Differences in survival were assessed using the log-rank test, and <span class="html-italic">p</span> values less than 0.05 were considered statistically significant (less than 0.05 are underlined). The short black lines on the survival curve indicate censored data.</p>
Full article ">
11 pages, 510 KiB  
Article
Significance as a Prognostic Factor of Eosinophil Count in Nasal Polyp Tissue in Patients with Chronic Rhinosinusitis Accompanied by Asthma
by Moo Keon Kim, Seok Hyun Cho, Ha Na Lee, Seon Min Jung and Jin Hyeok Jeong
J. Clin. Med. 2024, 13(19), 5849; https://doi.org/10.3390/jcm13195849 - 30 Sep 2024
Viewed by 449
Abstract
Background/Objectives: Patients with chronic rhinosinusitis (CRS) accompanied by asthma often show poor prognoses and require continuous management. This study aimed to assess the prognostic value of eosinophil counts in nasal polyp tissue for selecting individuals who would benefit from ongoing management in CRS [...] Read more.
Background/Objectives: Patients with chronic rhinosinusitis (CRS) accompanied by asthma often show poor prognoses and require continuous management. This study aimed to assess the prognostic value of eosinophil counts in nasal polyp tissue for selecting individuals who would benefit from ongoing management in CRS patients with asthma. Methods: Patients with asthma who underwent endoscopic sinus surgery for CRS with nasal polyps were included in the study. Eosinophil counts in nasal polyp tissues were quantified, and retrospective data were collected from laboratory and clinical findings, including endoscopic examinations, CT scans, and Japan Endoscopic Sinus Surgery Rating and Evaluation Committee (JESREC) scores. Disease control status was evaluated through endoscopic examination 6 months post-surgery. Results: A total of 42 patients were divided into two groups based on their disease management status 6 months post-operation: the well-control group (24 patients, 57.14%) and the poor-control group (18 patients, 42.86%). Demographics and laboratory findings did not show significant differences between the groups. However, the JESREC score (p = 0.04) and tissue eosinophil count (p = 0.02) were significantly different. Multivariate analysis identified tissue eosinophil count as the only risk factor associated with prognosis, with a cut-off value of 90/HPF. Conclusions: In CRS patients with asthma, high tissue eosinophil counts in nasal polyps were associated with poor disease control, which is the most potent predictor of prognosis. The assessment of eosinophil counts in nasal polyp tissue could aid in identifying patients who would benefit from continuous management and tailored interventions for improved outcomes. Full article
(This article belongs to the Section Otolaryngology)
Show Figures

Figure 1

Figure 1
<p>ROC (receiver operating characteristic) curve for prognosis of tissue eosinophil count (TEC) The value of area under curve (AUC) in TEC was 0.723. Using Youden’s index, the cut-off value of TEC that determined prognosis was 90/HPF.</p>
Full article ">
15 pages, 1894 KiB  
Article
Impact of the Disc Vacuum Phenomenon on Surgical Outcomes in Lumbar Spinal Stenosis: A Comparative Study between Endoscopic Decompression and Minimally Invasive Oblique Lateral Interbody Fusion
by Hyung Rae Lee, Kun Joon Lee, Seung Yup Lee and Jae Hyuk Yang
J. Clin. Med. 2024, 13(19), 5827; https://doi.org/10.3390/jcm13195827 - 29 Sep 2024
Viewed by 584
Abstract
Objective: This study investigated the influence of the vacuum phenomenon (VP) on surgical outcomes in patients with lumbar spinal stenosis, comparing minimally invasive oblique lateral interbody fusion (MIS OLIF) and endoscopic decompression. Methods: A cohort of 110 patients diagnosed with lumbar [...] Read more.
Objective: This study investigated the influence of the vacuum phenomenon (VP) on surgical outcomes in patients with lumbar spinal stenosis, comparing minimally invasive oblique lateral interbody fusion (MIS OLIF) and endoscopic decompression. Methods: A cohort of 110 patients diagnosed with lumbar spinal stenosis underwent either endoscopic decompression or MIS OLIF. Patients were classified into two groups based on the presence or absence of the VP on preoperative CT scans, non-VP (n = 42) and VP (n = 68). Radiologic and clinical outcomes, including back and leg pain assessed using the visual analogue scale (VAS), the Oswestry Disability Index (ODI), and the EuroQol-5 Dimension (Eq5D), were compared pre- and postoperatively over a 2-year follow-up period. Results: Preoperatively, the VP group exhibited significantly greater leg pain (p = 0.010), while no significant differences were observed in back pain or the ODI between the groups. In the non-VP group, decompression and fusion yielded similar outcomes, with decompression showing a better ODI score at 1 month (p = 0.018). In contrast, in the VP group, patients who underwent fusion showed significantly improved long-term leg pain outcomes compared to those who underwent decompression at both 1-year (p = 0.042) and 2-year (p = 0.017) follow-ups. Conclusions: The VP may indicate segmental instability and may play a role in the persistence of radiculopathy. Fusion surgery appears to offer better long-term relief in patients with the VP, whereas decompression alone is a viable option in non-VP cases. These findings suggest that the VP may be a useful factor in guiding surgical decision-making. Full article
(This article belongs to the Special Issue Current Progress and Future Directions of Spine Surgery)
Show Figures

Figure 1

Figure 1
<p>Patient selection flow chart. The figure outlines the process of including and excluding patients from the study cohort, from the initial screening to the final categorization into VP and non-VP groups.</p>
Full article ">Figure 2
<p>Illustration of the vacuum phenomenon (VP) and an endplate sclerosis assessment. The CT sagittal view shows the presence of the air in the disc space, indicating the VP. The most prominent VP cut was used for evaluation. Based on the ratio of the VP area to the disc area, the grades were categorized as follows: &lt;20% as Grade 1, 20–80% as Grade 2, and &gt;80% as Grade 3. Endplate sclerosis was noted when more than 20% of the vertebral endplate exhibited sclerotic changes. The VP with endplate sclerosis is shown in (<b>a</b>), the VP without endplate sclerosis in (<b>b</b>), non-VP with endplate sclerosis in (<b>c</b>), and non-VP without endplate sclerosis in (<b>d</b>).</p>
Full article ">Figure 3
<p>Comparison of clinical outcomes (back pain, leg pain, ODI, Eq5D) over time between decompression and fusion subgroups within the VP and non-VP groups. The blue asterisks (*) indicate points where <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">Figure 4
<p>Comparative cases of patients with and without the VP undergoing endoscopic decompression and OLIF. (<b>a</b>) Preoperative MRI shows severe L4-5 stenosis with no VP observed on CT (non-VP, indicated by red arrow). Postoperative MRI confirms adequate decompression following endoscopic decompression. (<b>b</b>) Preoperative MRI shows severe L4-5 stenosis, with Grade 2 VP detected on CT (VP sign indicated by yellow arrow). Postoperative MRI confirms adequate decompression following endoscopic decompression. (<b>c</b>) Preoperative MRI reveals severe stenosis at L4-5 due to degenerative spondylolisthesis (DSL), but no significant VP sign is observed on CT (non-VP, indicated by red arrow). MIS OLIF was performed at L4-5. (<b>d</b>) Preoperative MRI shows severe stenosis at L4-5, with Grade 2 VP confirmed on CT (VP sign indicated by yellow arrow). MIS OLIF was performed at L4-5.5.</p>
Full article ">
12 pages, 270 KiB  
Review
Clinical Evidence of Methods and Timing of Proper Follow-Up for Head and Neck Cancers
by Riccardo Gili, Simone Caprioli, Paola Lovino Camerino, Gianluca Sacco, Tommaso Ruelle, Daria Maria Filippini, Silvia Pamparino, Stefania Vecchio, Filippo Marchi, Lucia Del Mastro and Giuseppe Cittadini
Onco 2024, 4(4), 275-286; https://doi.org/10.3390/onco4040020 - 29 Sep 2024
Viewed by 370
Abstract
Background: For patients with head and neck squamous cell carcinoma (HNSCC), after a single or multi-modality treatment, a specific follow-up strategy is needed, but there is no agreement between the main international societies on the proper methods and timing of follow-up. Methods: We [...] Read more.
Background: For patients with head and neck squamous cell carcinoma (HNSCC), after a single or multi-modality treatment, a specific follow-up strategy is needed, but there is no agreement between the main international societies on the proper methods and timing of follow-up. Methods: We performed a descriptive review to evaluate the available data and compare the main guidelines, giving some practical guidance to perform effective personalized follow-up strategies. Results and Conclusions: While clinical and endoscopic follow-up alone seems to be appropriate for early-stage HNSCCs, the addition of close radiologic follow-up in locally advanced HNSCCs is still debated, as there are no data indicating that an earlier detection of recurrence correlates with increased survival, while it is mandatory in the first three-six months to define the response to treatment. For patients who have undergone conservative surgery or have major pathological risk factors, the incidence of locoregional recurrence is higher, and locoregional radiologic follow-up (magnetic resonance imaging is preferred to computed tomography) should be considered. Positron emission tomography may be useful in cases of suspected locoregional persistence of disease, differentiating it from post-irradiation outcomes. Distant radiological follow-up can be considered in the detection of the second primary in cases of specific risk factors and for virus-related tumors. For the latter, the use of circulating DNA should always be considered. A brain scan is not recommended without specific symptoms. For all patients who do not fall into the above categories, clinical and endoscopic follow-up should be proposed, reserving radiological investigations only at the onset of symptoms. Full article
16 pages, 633 KiB  
Systematic Review
Are Palliative Interventions Worth the Risk in Advanced Gastric Cancer? A Systematic Review
by Alicia A. Gingrich, Renceh B. Flojo, Allyson Walsh, Jennifer Olson, Danielle Hanson, Sarah B. Bateni, Sepideh Gholami and Amanda R. Kirane
J. Clin. Med. 2024, 13(19), 5809; https://doi.org/10.3390/jcm13195809 - 28 Sep 2024
Viewed by 611
Abstract
Background: Less than 25% of gastric cancers (GC) are discovered early, leading to limited treatment options and poor outcomes (27.8% mortality, 3.7% 5-year survival). Screening programs have improved cure rates, yet post-diagnosis treatment guidelines remain unclear (systemic chemotherapy versus surgery). The optimal type [...] Read more.
Background: Less than 25% of gastric cancers (GC) are discovered early, leading to limited treatment options and poor outcomes (27.8% mortality, 3.7% 5-year survival). Screening programs have improved cure rates, yet post-diagnosis treatment guidelines remain unclear (systemic chemotherapy versus surgery). The optimal type of palliative surgery (palliative gastrectomy (PG), surgical bypass (SB), endoscopic stenting (ES)) for long-term outcomes is also debated. Methods: A literature review was conducted using PubMed, MEDLINE, and EMBASE databases along with Google Scholar with the search terms “gastric cancer” and “palliative surgery” for studies post-1985. From the initial 1018 articles, multiple screenings narrowed it to 92 articles meeting criteria such as “metastatic, stage IV GC”, and intervention (surgery or chemotherapy). Data regarding survival and other long-term outcomes were recorded. Results: Overall, there was significant variation between studies but there were similarities of the conclusions reached. ES provided quick symptom relief, while PG showed improved overall survival (OS) only with adjuvant chemotherapy in a selective population. PG had higher mortality rates compared to SB, with ES having a reported 0% mortality, but OS improved with chemotherapy across both SB and PG. Conclusions: Less frail patients may experience an improvement in OS with palliative resection under limited circumstances. However, operative intervention without systemic chemotherapy is unlikely to demonstrate a survival benefit. Further research is needed to explore any correlations. Full article
(This article belongs to the Special Issue Gastrointestinal Cancer: Outcomes and Therapeutic Management)
Show Figures

Figure 1

Figure 1
<p>PRISMA Flow diagram of the selection of reviewed articles.</p>
Full article ">
18 pages, 5753 KiB  
Review
Biphenotypic Sinonasal Sarcoma with Orbital Invasion: A Literature Review and Modular System of Surgical Approaches
by Sergio Corvino, Oreste de Divitiis, Adriana Iuliano, Federico Russo, Giuseppe Corazzelli, Dana Cohen, Rosa Maria Di Crescenzo, Carmela Palmiero, Giuseppe Pontillo, Stefania Staibano, Diego Strianese, Andrea Elefante and Giuseppe Mariniello
Cancers 2024, 16(19), 3316; https://doi.org/10.3390/cancers16193316 - 27 Sep 2024
Viewed by 675
Abstract
Background: Biphenotypic sinonasal sarcoma is a rare low-grade tumor arising from the sinonasal tract, featuring locally aggressive biological behavior, with a tendency to invade the orbit and skull base. There are no defined guidelines of treatment; thus, the management varies among different institutions. [...] Read more.
Background: Biphenotypic sinonasal sarcoma is a rare low-grade tumor arising from the sinonasal tract, featuring locally aggressive biological behavior, with a tendency to invade the orbit and skull base. There are no defined guidelines of treatment; thus, the management varies among different institutions. The aim of the present study is to provide a modular system of surgical approaches according to the lesion pattern of growth from a literature review. Materials and Methods: A comprehensive and detailed literature review on the PubMed and Embase online electronic databases on biphenotypic sinonasal sarcoma with orbital invasion was conducted. A personal case exhibiting peculiar features was also added. Demographic (patient’s sex and age), clinical (presenting symptoms and time to treatment), neuroradiological (anatomical origin and pattern of growth), and treatment (type of treatment, surgical approach, extent of resection, peri- and postoperative complications, and adjuvant therapies) data, as well as clinical outcome, recurrence rates, and overall survival, were analyzed. Results: Thirty-one patients harboring biphenotypic sinonasal sarcoma with orbital invasion were identified. Tumors mainly affected female patients (66.7%) and a middle-aged population (median 55.2 years old). Simultaneous skull base involvement occurred in most cases (80.6%). Surgery was performed in all but one case (97%), as unique treatment (59%) or in association with radio—(23.5%) and/or chemotherapy (5.9%/2.9%), allowing for gross total tumor resection in most cases (66.7%). The endoscopic endonasal approach was the most adopted surgical corridor (51.7%). The local recurrence rate was 19.3%, and only two cases of tumor-related mortality occurred. Conclusions: Surgery is the only curative treatment, with the main goal to restore/improve/arrest progression of clinical manifestations. The endoscopic endonasal route represents the master approach for lesions confined to the midline. Microsurgical transcranial and endoscopic transorbital approaches have a complementary role for addressing the lesion’s component with large intracranial extension or affecting the paramedian aspect of the anterior cranial fossa and superior–lateral orbital compartment, respectively. The approach selection should be made case by case according to the tumor pattern of growth. Full article
(This article belongs to the Section Systematic Review or Meta-Analysis in Cancer Research)
Show Figures

Figure 1

Figure 1
<p>Flow chart showing the methods for the selection of the studies included in the review, following PRSIMA [<a href="#B10-cancers-16-03316" class="html-bibr">10</a>].</p>
Full article ">Figure 2
<p>Preoperative diagnostic images. (<b>A</b>,<b>B</b>) Head CT scan: (<b>A</b>) 3D reconstruction and (<b>B</b>) axial sequence: a bony fragment protruding into the left orbital cavity (white arrows) and the bony erosion of the roof (black arrows) are evident; (<b>C</b>–<b>E</b>) contrast-enhanced brain MRI: axial (<b>C</b>), coronal (<b>D</b>), and axial (<b>E</b>) sequences: inhomogeneous contrast-enhanced lesion arising from the ethmoid sinus, occupying and occluding the frontal sinus (<b>C</b>,<b>D</b>), with extension into the left orbit (<b>E</b>).</p>
Full article ">Figure 3
<p>(<b>A</b>,<b>B</b>) Histological evaluation revealed an unencapsulated tumor, infiltrating bone tissue (H&amp;E 10× and 20× respectively). (<b>C</b>) The tumor presented an infiltrative growth pattern and was composed of spindled cells forming medium-to-long fascicles, often with a herringbone pattern (H&amp;E 20×). Immunohistochemical examination revealed focal positivity for both S100 (<b>D</b>) and actin (<b>E</b>). The Ki67 index was low, about 2% (<b>F</b>).</p>
Full article ">Figure 4
<p><b>Schematic diagram.</b> Blue perpendicular dotted lines define four quadrants: the superior–lateral and inferior–lateral (green areas), which can be accessed through ETOA (endoscopic transorbital approach), and superior–medial and inferior–medial (red areas), which can be accessed via EEEA (extended endoscopic endonasal approach). Finally, the transcranial approach is indicated for lesions involving the superior–medial and superior–lateral quadrants (purple line) bilaterally. Red arrows indicate the main far limits of the EEEA in approaching the frontal sinus.</p>
Full article ">
18 pages, 5345 KiB  
Review
The Endoscopic Management of Zenker’s Diverticulum: A Comprehensive Review
by Giuseppe Dell’Anna, Ernesto Fasulo, Jacopo Fanizza, Rukaia Barà, Edoardo Vespa, Alberto Barchi, Paolo Cecinato, Lorenzo Fuccio, Vito Annese, Alberto Malesci, Francesco Azzolini, Silvio Danese and Francesco Vito Mandarino
Diagnostics 2024, 14(19), 2155; https://doi.org/10.3390/diagnostics14192155 - 27 Sep 2024
Viewed by 376
Abstract
Zenker’s Diverticulum (ZD) is the most common hypopharyngeal diverticulum; however, it is often underdiagnosed. It results from the herniation of the mucosa and submucosa through Killian’s Triangle. Dysphagia is the primary symptom, occurring in 80–90% of cases. The primary goal of treatment is [...] Read more.
Zenker’s Diverticulum (ZD) is the most common hypopharyngeal diverticulum; however, it is often underdiagnosed. It results from the herniation of the mucosa and submucosa through Killian’s Triangle. Dysphagia is the primary symptom, occurring in 80–90% of cases. The primary goal of treatment is to transect the cricopharyngeal muscle (CM) and connect the ZD cavity to the esophageal lumen. Traditional treatments include surgical open transcervical diverticulectomy and CM septomyotomy, using rigid or flexible endoscopes. However, surgery is burdened by technical difficulties and not negligible rates of adverse events (AEs). For this reason, endoscopic techniques for ZD treatment have gained traction in recent years. Flexible endoscopic septum division (FESD), introduced nearly 20 years ago, involves a full-thickness incision of the diverticular septum. The advent of third-space endoscopy has led to the application of these techniques to ZD treatment as well. Zenker-POEM (Z-POEM) and, subsequently, Per Oral Endoscopic Septomyotomy (POES) have been developed. Hybrid techniques, such as Peroral Endoscopic Diverticulotomy (POED) and tunneling-free methods, represent additional ZD treatment options. This review outlines the armamentarium of ZD endoscopic management, summarizing the characteristics of these techniques, their benefits and limitations, and highlighting future research directions. Full article
(This article belongs to the Special Issue Advances in the Diagnostic Imaging of Gastrointestinal Diseases)
Show Figures

Figure 1

Figure 1
<p>Technical steps of flexible endoscopic septum division (FESD). (<b>A</b>) Visualization of the septum that separates the Zenker’s Diverticulum (ZD) from the esophagus and which contains the cricopharyngeal muscle (CM); a transparent hood is usually placed on the tip of the endoscope to stabilize positioning. (<b>B</b>,<b>C</b>) Septotomy performed by a J-shaped knife. (<b>D</b>,<b>E</b>) Final stages of the septotomy with exposure of the CM fibers. (<b>F</b>) Placement of through-the-scope clips at the base of the diverticulum at the end of the septotomy. The copyright of the image belongs to the authors.</p>
Full article ">Figure 2
<p>Technical steps of Peroral Endoscopic Septotomy (POES). (<b>A</b>) Visualization of the Zenker’s Diverticulum septum by placing a transparent distal hood. (<b>B</b>) Submucosal injection is performed just above the septum. (<b>C</b>) The mucosal entry is performed directly on the septum with a J-shaped knife. (<b>D</b>) Submucosal tunneling is created along both sides of the septum, terminating from 1 to 3 cm distal to the base of the ZD. (<b>E</b>–<b>H</b>) Exposure of the cricopharyngeal muscle and subsequent myotomy down to the base of the ZD and into the esophageal muscle. (<b>H</b>) Final closure of the mucosal defect with through-the-scope clips. The copyright of the image belongs to the authors.</p>
Full article ">Figure 3
<p>Technical steps of Submucosal INjection Guided septomyotomy (SING technique). (<b>A</b>) Visualization of the septum by using a transparent distal hood and by inserting a nasogastric/orogastric tube into the esophageal lumen. (<b>B</b>,<b>C</b>) A full-thickness septotomy with a J-shaped knife is performed for about two-thirds of the septum’s length. (<b>D</b>–<b>G</b>) A complete CM myotomy is performed, extending approximately 10 mm into the esophageal muscle, with continuous submucosal injection on both sides to precisely identify the muscle fibers. (<b>H</b>) Placement of through-the-scope clips to close the mucosal defect. The copyright of the image belongs to the authors.</p>
Full article ">
20 pages, 658 KiB  
Systematic Review
Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Urogynecological Surgery: A Systematic Review
by Lorenzo Vacca, Eleonora Rosato, Riccardo Lombardo, Paolo Geretto, Simone Albisinni, Riccardo Campi, Sabrina De Cillis, Laura Pelizzari, Maria Lucia Gallo, Gianluca Sampogna, Andrea Lombisani, Giuseppe Campagna, Alessandro Giammo, Vincenzo Li Marzi, Cosimo De Nunzio and Young Research Group of the Italian Society of Urodynamics
J. Clin. Med. 2024, 13(19), 5707; https://doi.org/10.3390/jcm13195707 - 25 Sep 2024
Viewed by 766
Abstract
Background: Minimally invasive surgery could improve cosmetic outcomes and reduce the risks of surgical injury with less postoperative pain and a quicker patient’s discharge. Recently, transvaginal natural orifice transluminal endoscopic surgery (vNOTES) has been introduced in urogynecology with exciting results. Evidence Acquisition: After [...] Read more.
Background: Minimally invasive surgery could improve cosmetic outcomes and reduce the risks of surgical injury with less postoperative pain and a quicker patient’s discharge. Recently, transvaginal natural orifice transluminal endoscopic surgery (vNOTES) has been introduced in urogynecology with exciting results. Evidence Acquisition: After PROSPERO registration (n°CRD42023406815), we performed a comprehensive literature search on Pubmed, Embase, and Cochrane CENTRAL, including peer-reviewed studies evaluating transvaginal natural orifice transluminal endoscopic surgery. No limits on time or type of study were applied. Evidence synthesis: Overall, 12 manuscripts were included in the analysis. Seven studies evaluated uterosacral ligament suspension, four studies evaluated sacral colpopexy, three evaluated sacrospinous ligament suspension, and one study evaluated lateral suspension. Overall success rates were high (>90%); however, definitions of success were heterogeneous. In terms of complication, most of the studies reported low-grade complications (Clavien–Dindo I and II); only two patients needed mesh removal because of mesh exposure. The risk of bias of the trials was rated in the medium to high-risk category. Conclusions: The present review highlights important initial results for vNOTES. Future randomized clinical trials are needed to better define its role in the management of urogynecological procedures. Full article
(This article belongs to the Special Issue Pelvic Organ Prolapse: Current Progress and Clinical Challenges)
Show Figures

Figure 1

Figure 1
<p>PRISMA flow chart. * Pubmed, Embase, Google Scholar, Web of Science, and Cochrane CENTRAL. ** Two authors performed the screening.</p>
Full article ">
20 pages, 14243 KiB  
Review
EUS-Guided Radiofrequency Ablation Therapy for Pancreatic Neoplasia
by Mihai Rimbaș, Andra-Cristiana Dumitru, Giulia Tripodi and Alberto Larghi
Diagnostics 2024, 14(19), 2111; https://doi.org/10.3390/diagnostics14192111 - 24 Sep 2024
Viewed by 380
Abstract
Radiofrequency ablation (RFA) under endoscopic ultrasound (EUS) guidance has been developed and utilized over the last decade to provide the loco-regional treatment of solid and cystic pancreatic neoplastic lesions. The advantage of this approach relies on the close proximity of the EUS transducer [...] Read more.
Radiofrequency ablation (RFA) under endoscopic ultrasound (EUS) guidance has been developed and utilized over the last decade to provide the loco-regional treatment of solid and cystic pancreatic neoplastic lesions. The advantage of this approach relies on the close proximity of the EUS transducer to the target pancreatic lesion, which, coupled with the development of specifically designed RFA ablation devices, has made the procedure minimally invasive, with a clear reduction in adverse events as compared to the high morbidity of the surgical approach. EUS-RFA has been applied so far to pancreatic functional and non-functional neuroendocrine neoplasms, pancreatic ductal adenocarcinoma or metastases to the pancreas, and pancreatic neoplastic cysts. Excluding neuroendocrine tumors, for other indications, most of these procedures have been performed in patients who refused surgery or were at high surgical risk. More studies evaluating EUS-RFA in selected patients, not at surgical risk, are gradually becoming available and will pave the road to extend the indications for this therapeutic approach, also in association with other oncological therapies. The present manuscript will critically review the available evidence in the field of the EUS-guided RFA of solid and cystic pancreatic neoplasms. Full article
(This article belongs to the Special Issue Endoscopic Ultrasound Guided Techniques in Pancreatic Diseases)
Show Figures

Figure 1

Figure 1
<p>The Habib catheter for EUS-guided radiofrequency ablation (EMcision Ltd., London, UK) (reproduced with permission from [<a href="#B7-diagnostics-14-02111" class="html-bibr">7</a>].</p>
Full article ">Figure 2
<p>The EUS-guided EUSRA radiofrequency ablation needle from Taewoong Medical with the active tip exposed (arrows) (reproduced with permission from [<a href="#B7-diagnostics-14-02111" class="html-bibr">7</a>].</p>
Full article ">Figure 3
<p>(<b>A</b>). Contrast-enhanced endoscopic ultrasound of a 13 mm insulinoma in the uncinate process of the pancreas; (<b>B</b>). EUS view of the EUSRA 19G RFA needle (arrow) inserted into the right portion the tumor; (<b>C</b>). EUS view of the EUSRA 19G RFA needle (arrow) inside the left portion the tumor. (<b>D</b>). Final aspect at the end of the procedure.</p>
Full article ">Figure 4
<p>(<b>A</b>). Tip of the EUSRA 19G RFA needle inside of a pancreatic head ductal adenocarcinoma (arrow). (<b>B</b>). Initiation of the radiofrequency ablation as demonstrated by the appearance of white bubbles. (<b>C</b>). Increasing of the ablation site as demonstrated by an increase in the amount of the area with white bubbles. (<b>D</b>). Final aspect at the end of the treatment session after targeting three different tumor areas.</p>
Full article ">Figure 5
<p>(<b>A</b>). The EUSRA 19G radiofrequency device inserted into a pancreatic 15 mm renal cell metastasis (arrow). (<b>B</b>). Final aspect after completion of the radiofrequency ablation procedure.</p>
Full article ">Figure 6
<p>(<b>A</b>,<b>B</b>). Small mural nodules within a pancreatic neoplastic cystic lesion (arrows) avidly taking contrast as revealed by contrast-enhanced EUS; (<b>C</b>). EUS view showing the tip of the EUSRA 19G RFA surrounded by white bubbles (arrow), indicating the beginning of the RFA energy application. (<b>D</b>). Follow-up contrast-enhanced endoscopic ultrasound of the same neoplastic cystic lesion after radiofrequency ablation treatment resulting in the disappearance of both mural nodules.</p>
Full article ">
13 pages, 1254 KiB  
Article
Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A “Real-Life” Observational Study
by Eugenio De Corso, Dario Antonio Mele, Angela Rizzi, Camilla Spanu, Marco Corbò, Serena Pisciottano, Rodolfo Francesco Mastrapasqua, Silvia Baroni, Davide Paolo Porru, Gabriele De Maio, Alberta Rizzuti, Giuseppe Alberto Di Bella, Augusta Ortolan, Matteo Bonini, Francesca Cefaloni, Cristina Boccabella, Francesco Lombardi, Raffaella Chini, Cristiano Caruso, Marco Panfili and Jacopo Galliadd Show full author list remove Hide full author list
J. Pers. Med. 2024, 14(9), 1014; https://doi.org/10.3390/jpm14091014 - 23 Sep 2024
Viewed by 597
Abstract
Background/Objectives: Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor (IL-5Rα), leading to the rapid depletion of blood eosinophils. RCTs have demonstrated efficacy in patients with severe eosinophilic asthma (SEA). The aim of this study was to assess the efficacy of benralizumab [...] Read more.
Background/Objectives: Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor (IL-5Rα), leading to the rapid depletion of blood eosinophils. RCTs have demonstrated efficacy in patients with severe eosinophilic asthma (SEA). The aim of this study was to assess the efficacy of benralizumab on sinonasal outcomes in a real-life setting in patients with SEA and concomitant chronic rhinosinusitis with nasal polyps (CRSwNP). Methods: We included 25 patients (mean age: 57.47 years, range: 35–77, F/M = 12:13) who were prescribed 30 mg benralizumab every month for the first three administrations and then every 2 months. The primary endpoint was to evaluate changes in the SinoNasal Outcome Test-22 (SNOT-22) and nasal polyp score (NPS) over a 24-month treatment period. Secondary endpoints included measuring the effects on nasal obstruction and impaired sense of smell. Results: The mean NPS score decreased significantly from 5.11 ± 1.84 at baseline to 2.37 ± 1.96 at 24 months. The mean SNOT-22 decreased from 57 ± 15.30 at baseline to 26 ± 16.73 at 24 months. The SSIT-16 mean score improved with an increase in olfactory performance from 5.23 ± 2.58 at baseline to 7 ± 3.65 at 24 months. Moreover, 8/25 patients (32%) required rescue treatment with systemic steroids and 2 patients required endoscopic sinus surgery. Conclusions: While the improvement may not seem optimal at 12 months, a progressive enhancement was noted during the second year of treatment. Despite our data showing an improvement in quality of life and a reduction in the size of nasal polyps, no significant improvement in olfactory sensitivity was observed. In addition, in several patients, rescue treatments were required to maintain control of nasal and sinus symptoms. A careful risk–benefit assessment is therefore needed when deciding to continue treatment, weighing the potential for further improvement against the risks of complications. Such decisions should always be made in the context of a multidisciplinary team. Full article
(This article belongs to the Special Issue Respiratory Health and Chronic Disease Management)
Show Figures

Figure 1

Figure 1
<p>Nasal polyp endoscopic score (NPS) (<b>a</b>) and Sino-nasal Outcome Test−22 (SNOT−22) (<b>b</b>) fluctuation over time.</p>
Full article ">Figure 2
<p>VAS nasal obstruction (<b>a</b>), rhinorrhea (<b>b</b>), facial pain (<b>c</b>), and sleep disturbance (<b>d</b>) fluctuations over time.</p>
Full article ">Figure 2 Cont.
<p>VAS nasal obstruction (<b>a</b>), rhinorrhea (<b>b</b>), facial pain (<b>c</b>), and sleep disturbance (<b>d</b>) fluctuations over time.</p>
Full article ">Figure 3
<p>Sniffin Sticks (<b>a</b>) and VAS olfaction (<b>b</b>) fluctuations over time.</p>
Full article ">
14 pages, 425 KiB  
Article
Prospective Evaluation of Transsphenoidal Pituitary Surgery in Patients with Cushing’s Disease: Delayed Remission and the Role of Postsurgical Cortisol as a Predictive Factor
by Athanasios Saratziotis, Maria Baldovin, Claudia Zanotti, Sara Munari, Diego Cazzador, Enrico Alexandre, Luca Denaro, Jiannis Hajiioannou and Enzo Emanuelli
Healthcare 2024, 12(18), 1900; https://doi.org/10.3390/healthcare12181900 - 22 Sep 2024
Viewed by 588
Abstract
Background. Transsphenoidal surgery is the treatment of choice for Cushing’s disease. Successful surgery is associated with subnormal postoperative serum cortisol concentrations and cortisoluria levels, which may guide decisions regarding immediate reoperation. Remission is defined as the biochemical reversal of hypercortisolism with the re-emergence [...] Read more.
Background. Transsphenoidal surgery is the treatment of choice for Cushing’s disease. Successful surgery is associated with subnormal postoperative serum cortisol concentrations and cortisoluria levels, which may guide decisions regarding immediate reoperation. Remission is defined as the biochemical reversal of hypercortisolism with the re-emergence of diurnal circadian rhythm. Methods. A single-center prospective cohort study was conducted among thirty-three patients who underwent transsphenoidal pituitary surgery for Cushing’s disease. Postoperative surgical outcomes, daily morning cortisolemia, and 24 h urinary-free cortisol from the first to the fifth morning were evaluated. Results. All patients underwent surgery, with a remission rate of 81.2%. Of the 26 patients who achieved early remission, 92% remained in remission. Two patients (7.7%) showed recurrence of Cushing’s disease during a mean follow-up of 81.7 months. Early postoperative hypocortisolism suggests complete removal of the tumor, correlating with high rates of remission (p < 0.001). Also, in 12.5% of patients with early cortisol values >138 nmol/L, there was a gradual late remission. Conclusions. In our cohort of patients, the endoscopic transsphenoidal approach was safe and effective in the treatment of Cushing’s disease. We demonstrated that serum and urinary cortisol concentrations did not experience significant fluctuations from the first to the fifth day. This constitutes an accurate predictor of durable remission, comprising a distinctive finding in the intermediate term by our team. Full article
Show Figures

Figure 1

Figure 1
<p>Evaluation of all the examined parameters (blood, urine) from the first to the fifth day from the same patients. (<b>a</b>) Postsurgery cortisolemia in nmol/L on the y-axis, and from the first to the fifth day on the x-axis. (<b>b</b>) Postsurgery cortisoluria (nmol/24 h) on the y-axis, and from the first to the fifth day on the x-axis. Pod, Postoperative day.</p>
Full article ">
Back to TopTop